**Supplementary Table 2. Newcastle-Ottawa scale score quality assessment of the included cohort studies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Author, year** | **Selection (4 points)** | **Comparability (2 points)** | **Outcome (3 points)** | **Score (up to 9 points)** |
| Simon 2020[39] | 4 | 2 | 3 | 9 |
| Shin 2020[25] | 3 | 2 | 3 | 8 |
| Lee 2020[18] | 4 | 2 | 2 | 8 |
| Tsoi 2019[16] | 4 | 2 | 3 | 9 |
| Lee 2019[19] | 3 | 2 | 3 | 8 |
| Du 2019[20] | 4 | 2 | 3 | 9 |
| Tseng 2018[27] | 3 | 2 | 3 | 8 |
| Simon 2018[23] | 3 | 2 | 3 | 8 |
| Lin 2018[28] | 2 | 2 | 2 | 6 |
| Hwang 2018[21] | 4 | 2 | 3 | 9 |
| Ho 2018[15] | 3 | 2 | 2 | 7 |
| Oh 2017[14] | 3 | 1 | 1 | 5 |
| Lee 2017[30] | 3 | 2 | 2 | 7 |
| Lee 2017[24] | 3 | 2 | 2 | 7 |
| Petrick 2015[22] | 2 | 2 | 3 | 7 |
| Sahasrabuddhe 2012[33] | 2 | 2 | 3 | 7 |
| Friis 2003[35] | 2 | 2 | 2 | 6 |

References

14. Lee TY, Hsu YC, Tseng HC, Lin JT, Wu MS, Wu CY. Association of Daily Aspirin Therapy With Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis C Virus Infection. Clin Gastroenterol Hepatol 2020;18(12):2784-2792.e7. doi: 10.1016/j.cgh.2020.04.036. PMID: 32360983.

15. Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, Wu MS, *et al*. Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. JAMA Intern Med 2019;179(5):633-640. doi: 10.1001/jamainternmed.2018.8342. PMID: 30882847.

16. Du ZQ, Zhao JZ, Dong J, Bi JB, Ren YF, Zhang J, *et al*. Effect of low-dose aspirin administration on long-term survival of cirrhotic patients after splenectomy: A retrospective single-center study. World J Gastroenterol 2019;25(28):3798-3807. doi: 10.3748/wjg.v25.i28.3798. PMID: 31391774.

18. Lee M, Chung GE, Lee JH, Oh S, Nam JY, Chang Y, *et al*. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. Hepatology 2017;66(5):1556-1569. doi: 10.1002/hep.29318. PMID: 28617992.

19. Petrick JL, Sahasrabuddhe VV, Chan AT, Alavanja MC, Beane-Freeman LE, Buring JE, *et al*. NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project. Cancer Prev Res (Phila) 2015;8(12):1156-1162. doi: 10.1158/1940-6207.Capr-15-0126. PMID: 26391917.

20. Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, Fuchs CS, *et al*. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncol 2018;4(12):1683-1690. doi: 10.1001/jamaoncol.2018.4154. PMID: 30286235.

21. Lee M, Chung GE, Lee JH, Oh S, Nam JY, Chang Y, *et al*. Antiplatelet Therapy and the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Antiviral Treatment. Hepatology 2017;66(5):1556-1569. doi: 10.1002/hep.29318. PMID: 28617992.

22. García Rodríguez LA, Martín-Pérez M, Hennekens CH, Rothwell PM, Lanas A. Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. PloS One 2016;11(8):e0160046. doi: 10.1371/journal.pone.0160046. PMID: 27490468.

23. Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med 2016;164(12):826-835. doi: 10.7326/m15-2112. PMID: 27064261.

24. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, *et al*. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328(25):1797-1801. doi: 10.1056/nejm199306243282501. PMID: 7684822.

25. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG, *et al*. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003;37(3):520-527. doi: 10.1053/jhep.2003.50093. PMID: 12601348.

27. Tseng CH. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver Int 2018;38(11):2018-2027. doi: 10.1111/liv.13872. PMID: 29956875.

28. Lin YS, Yeh CC, Huang SF, Chou YS, Kuo LT, Sung FC, *et al*. Aspirin associated with risk reduction of secondary primary cancer for patients with head and neck cancer: A population-based analysis. PloS One 2018;13(8):e0199014. doi: 10.1371/journal.pone.0199014. PMID: 30133455.

30. Lee TY, Wu JC, Yu SH, Lin JT, Wu MS, Wu CY. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. Int J Cancer 2017;141(7):1307-1314. doi: 10.1002/ijc.30784. PMID: 28509327.

33. Sahasrabuddhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, Park Y, *et al*. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst 2012;104(23):1808-1814. doi: 10.1093/jnci/djs452. PMID: 23197492.

35. Friis S, Sørensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003;88(5):684-688. doi: 10.1038/sj.bjc.6600760. PMID: 12618874.

39. Simon TG, Duberg AS, Aleman S, Chung RT, Chan AT, Ludvigsson JF. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. N Engl J Med 2020;382(11):1018-1028. doi: 10.1056/NEJMoa1912035. PMID: 32160663.